CYP17A1 and prostate carcinoma: Abiraterone acetate (ABI) is a selective androgen biosynthesis inhibitor that potently and irreversibly blocks Cyp17 resulting in virtually undetectable serum and intratumoral androgen production in the adrenals, testes and prostate cancer cells [2, 3].